High levels of lipoprotein(a) and hsCRP tied to increased risk of cardiovascular events

The study included 10,424 patients with both Lp(a) and hsCRP measurements. To investigate the relationship between hsCRP, Lp(a), and adverse cardiac and cerebrovascular events (all-cause death, MACE, ischemic stroke, myocardial infarction, and revascularization), the researchers performed Cox proportional hazards models, and Kaplan-Meier analysis was performed.

The study led to the following findings:

• 20.5% of MACCE occurred during five years of follow-up.
• Increased levels of Lp(a) and hsCRP were associated with increased risks of MACCE.
• There might be a remarkable interaction between Lp(a) and hsCRP.
• The reearchers observed a significant higher risk of MACCE with Lp(a) 15–29.9 mg/dL (HR: 1.18) and Lp(a) ≥30mg/dL (HR: 1.20) in the setting of hsCRP≥2mg/L, when hsCRP was <2 mg/L with Lp(a) 15–29.9 mg/dL (HR: 0.94) and Lp(a) ≥30 mg/dL (HR: 1.12) such association was attenuated
• Patients with a dual elevation of these two biomarkers had a significantly higher MACCE risk compared with the reference group (Lp(a) < 15 mg/dL and hsCRp<2 mg/L) when Lp(a) and hsCRP were combined for risk stratification.

Increased Lp(a) and hsCRP are individually associated with an increased risk of cardiovascular events. In patients with higher hsCRP concentrations, the association between Lp(a) and cardiovascular risk might be stronger.

The findings led researchers to conclude that concurrently evaluation of Lp(a) and hsCRP may help risk stratification.

Reference:

https://doi.org/10.1016/j.atherosclerosis.2022.10.013